These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30411431)

  • 1. Predictive model algorithms identifying early and advanced stage ER+/HER2- breast cancer in claims data.
    Beachler DC; de Luise C; Yin R; Gangemi K; Cochetti PT; Lanes S
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):171-178. PubMed ID: 30411431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of an Algorithm for Identifying Patients with Hemophilia A in an Administrative Claims Database.
    Lyons J; Desai V; Xu Y; Ridgeway G; Finkle W; Solari P; Sullivan S; Lanes S
    Value Health; 2018 Sep; 21(9):1098-1103. PubMed ID: 30224115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of predictive models to identify advanced-stage cancer patients in a US healthcare claims database.
    Esposito DB; Russo L; Oksen D; Yin R; Desai VCA; Lyons JG; Verpillat P; Peñalvo JL; Lamy FX; Lanes S
    Cancer Epidemiol; 2019 Aug; 61():30-37. PubMed ID: 31128428
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer.
    Asogan AB; Hong GS; Arni Prabhakaran SK
    Singapore Med J; 2017 Mar; 58(3):145-149. PubMed ID: 27029805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study.
    DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA; DaCosta Byfield S; Buck PO; Blauer-Peterson C; Poston SA
    J Oncol Pract; 2016 Feb; 12(2):159-67. PubMed ID: 26395563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the subtype of breast cancer affect the diagnostic performance of axillary ultrasound for nodal staging in breast cancer patients?
    Vane MLG; van Nijnatten TJA; Nelemans PJ; Lobbes MBI; van Roozendaal LM; Kooreman LFS; Keymeulen KBMI; Smidt ML; Schipper RJ
    Eur J Surg Oncol; 2019 Apr; 45(4):573-577. PubMed ID: 30732971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.
    Pajenga E; Rexha T; Çeliku S; Ugrinska A; Bejtja G
    Cent Eur J Public Health; 2016 Sep; 24(3):171-175. PubMed ID: 27760283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity and risk of the less commonly diagnosed subtypes of breast cancer.
    Stark A; Schultz D; Kapke A; Nadkarni P; Burke M; Linden M; Raju U
    Eur J Surg Oncol; 2009 Sep; 35(9):928-35. PubMed ID: 19121564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An algorithm for the use of Medicare claims data to identify women with incident breast cancer.
    Nattinger AB; Laud PW; Bajorunaite R; Sparapani RA; Freeman JL
    Health Serv Res; 2004 Dec; 39(6 Pt 1):1733-49. PubMed ID: 15533184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of algorithms to identify newly diagnosed type 1 and type 2 diabetes in pediatric population using electronic medical records and claims data.
    Teltsch DY; Fazeli Farsani S; Swain RS; Kaspers S; Huse S; Cristaldi C; Nordstrom BL; Brodovicz KG
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):234-243. PubMed ID: 30677205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
    Guérin A; Hao Y; Tang D; Peeples M; Fang A; Kageleiry A; Koo V; Li N; Wu EQ
    Expert Opin Pharmacother; 2016 Jun; 17(9):1189-96. PubMed ID: 27052735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
    Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
    World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
    Parise CA; Caggiano V
    Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.